Up-Regulation of Endothelial Delta-like 4 Expression Correlates with Vessel Maturation in Bladder Cancer

Purpose: Angiogenesis and vascular endothelial growth factor (VEGF) expression are associated with a poor outcome in bladder cancer. To understand more about the mechanisms, we studied the role of delta-like 4 (DLL4), an endothelial-specific ligand of the Notch signaling pathway, in bladder cancer a...

Full description

Saved in:
Bibliographic Details
Published inClinical cancer research Vol. 12; no. 16; pp. 4836 - 4844
Main Authors PATEL, Nilay S, DOBBIE, Michael S, ROCHESTER, Mark, STEERS, Graham, POULSOM, Richard, LE MONNIER, Karena, CRANSTON, David W, LI, Ji-Liang, HARRIS, Adrian L
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Association for Cancer Research 15.08.2006
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Purpose: Angiogenesis and vascular endothelial growth factor (VEGF) expression are associated with a poor outcome in bladder cancer. To understand more about the mechanisms, we studied the role of delta-like 4 (DLL4), an endothelial-specific ligand of the Notch signaling pathway, in bladder cancer angiogenesis. Experimental Design: The expression of DLL4, CD34, and VEGF were studied in a cohort of 60 bladder tumors and 10 normal samples using quantitative PCR. In situ hybridization was used to study the pattern of DLL4 expression in 22 tumor and 9 normal samples. Serial sections were also stained for CD34 and α-smooth muscle actin (α-SMA) using conventional immunohistochemistry. Results: The expression of DLL4 was significantly up-regulated in superficial ( P < 0.01) and invasive ( P < 0.05) bladder cancers. DLL4 expression significantly correlated with CD34 ( P < 0.001) and VEGF ( P < 0.001) expression. The in situ hybridization studies showed that DLL4 was highly expressed within bladder tumor vasculature. Additionally, DLL4 expression significantly correlated with vessel maturation as judged by periendothelial cell expression of α-SMA, 98.7% of DLL4-positive tumor vessels coexpressed α-SMA, compared with 64.5% of DLL4-negative tumor vessels ( P < 0.001). High DLL4 expression may have prognostic value in superficial and invasive bladder. Conclusion: DLL4 expression is associated with vascular differentiation in bladder cancer; thus, targeting DLL4 may be a novel antiangiogenic therapy.
AbstractList Purpose: Angiogenesis and vascular endothelial growth factor (VEGF) expression are associated with a poor outcome in bladder cancer. To understand more about the mechanisms, we studied the role of delta-like 4 (DLL4), an endothelial-specific ligand of the Notch signaling pathway, in bladder cancer angiogenesis. Experimental Design: The expression of DLL4, CD34, and VEGF were studied in a cohort of 60 bladder tumors and 10 normal samples using quantitative PCR. In situ hybridization was used to study the pattern of DLL4 expression in 22 tumor and 9 normal samples. Serial sections were also stained for CD34 and α-smooth muscle actin (α-SMA) using conventional immunohistochemistry. Results: The expression of DLL4 was significantly up-regulated in superficial (P < 0.01) and invasive (P < 0.05) bladder cancers. DLL4 expression significantly correlated with CD34 (P < 0.001) and VEGF (P < 0.001) expression. The in situ hybridization studies showed that DLL4 was highly expressed within bladder tumor vasculature. Additionally, DLL4 expression significantly correlated with vessel maturation as judged by periendothelial cell expression of α-SMA, 98.7% of DLL4-positive tumor vessels coexpressed α-SMA, compared with 64.5% of DLL4-negative tumor vessels (P < 0.001). High DLL4 expression may have prognostic value in superficial and invasive bladder. Conclusion: DLL4 expression is associated with vascular differentiation in bladder cancer; thus, targeting DLL4 may be a novel antiangiogenic therapy.
PURPOSEAngiogenesis and vascular endothelial growth factor (VEGF) expression are associated with a poor outcome in bladder cancer. To understand more about the mechanisms, we studied the role of delta-like 4 (DLL4), an endothelial-specific ligand of the Notch signaling pathway, in bladder cancer angiogenesis.EXPERIMENTAL DESIGNThe expression of DLL4, CD34, and VEGF were studied in a cohort of 60 bladder tumors and 10 normal samples using quantitative PCR. In situ hybridization was used to study the pattern of DLL4 expression in 22 tumor and 9 normal samples. Serial sections were also stained for CD34 and alpha-smooth muscle actin (alpha-SMA) using conventional immunohistochemistry.RESULTSThe expression of DLL4 was significantly up-regulated in superficial (P < 0.01) and invasive (P < 0.05) bladder cancers. DLL4 expression significantly correlated with CD34 (P < 0.001) and VEGF (P < 0.001) expression. The in situ hybridization studies showed that DLL4 was highly expressed within bladder tumor vasculature. Additionally, DLL4 expression significantly correlated with vessel maturation as judged by periendothelial cell expression of alpha-SMA, 98.7% of DLL4-positive tumor vessels coexpressed alpha-SMA, compared with 64.5% of DLL4-negative tumor vessels (P < 0.001). High DLL4 expression may have prognostic value in superficial and invasive bladder.CONCLUSIONDLL4 expression is associated with vascular differentiation in bladder cancer; thus, targeting DLL4 may be a novel antiangiogenic therapy.
Purpose: Angiogenesis and vascular endothelial growth factor (VEGF) expression are associated with a poor outcome in bladder cancer. To understand more about the mechanisms, we studied the role of delta-like 4 (DLL4), an endothelial-specific ligand of the Notch signaling pathway, in bladder cancer angiogenesis. Experimental Design: The expression of DLL4, CD34, and VEGF were studied in a cohort of 60 bladder tumors and 10 normal samples using quantitative PCR. In situ hybridization was used to study the pattern of DLL4 expression in 22 tumor and 9 normal samples. Serial sections were also stained for CD34 and α-smooth muscle actin (α-SMA) using conventional immunohistochemistry. Results: The expression of DLL4 was significantly up-regulated in superficial ( P < 0.01) and invasive ( P < 0.05) bladder cancers. DLL4 expression significantly correlated with CD34 ( P < 0.001) and VEGF ( P < 0.001) expression. The in situ hybridization studies showed that DLL4 was highly expressed within bladder tumor vasculature. Additionally, DLL4 expression significantly correlated with vessel maturation as judged by periendothelial cell expression of α-SMA, 98.7% of DLL4-positive tumor vessels coexpressed α-SMA, compared with 64.5% of DLL4-negative tumor vessels ( P < 0.001). High DLL4 expression may have prognostic value in superficial and invasive bladder. Conclusion: DLL4 expression is associated with vascular differentiation in bladder cancer; thus, targeting DLL4 may be a novel antiangiogenic therapy.
Angiogenesis and vascular endothelial growth factor (VEGF) expression are associated with a poor outcome in bladder cancer. To understand more about the mechanisms, we studied the role of delta-like 4 (DLL4), an endothelial-specific ligand of the Notch signaling pathway, in bladder cancer angiogenesis. The expression of DLL4, CD34, and VEGF were studied in a cohort of 60 bladder tumors and 10 normal samples using quantitative PCR. In situ hybridization was used to study the pattern of DLL4 expression in 22 tumor and 9 normal samples. Serial sections were also stained for CD34 and alpha-smooth muscle actin (alpha-SMA) using conventional immunohistochemistry. The expression of DLL4 was significantly up-regulated in superficial (P < 0.01) and invasive (P < 0.05) bladder cancers. DLL4 expression significantly correlated with CD34 (P < 0.001) and VEGF (P < 0.001) expression. The in situ hybridization studies showed that DLL4 was highly expressed within bladder tumor vasculature. Additionally, DLL4 expression significantly correlated with vessel maturation as judged by periendothelial cell expression of alpha-SMA, 98.7% of DLL4-positive tumor vessels coexpressed alpha-SMA, compared with 64.5% of DLL4-negative tumor vessels (P < 0.001). High DLL4 expression may have prognostic value in superficial and invasive bladder. DLL4 expression is associated with vascular differentiation in bladder cancer; thus, targeting DLL4 may be a novel antiangiogenic therapy.
Author Mark Rochester
Richard Poulsom
Karena Le Monnier
Adrian L. Harris
Nilay S. Patel
David W. Cranston
Ji-Liang Li
Michael S. Dobbie
Graham Steers
Author_xml – sequence: 1
  givenname: Nilay S
  surname: PATEL
  fullname: PATEL, Nilay S
  organization: Growth Factor Group. Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, United Kingdom
– sequence: 2
  givenname: Michael S
  surname: DOBBIE
  fullname: DOBBIE, Michael S
  organization: Growth Factor Group. Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, United Kingdom
– sequence: 3
  givenname: Mark
  surname: ROCHESTER
  fullname: ROCHESTER, Mark
  organization: Growth Factor Group. Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, United Kingdom
– sequence: 4
  givenname: Graham
  surname: STEERS
  fullname: STEERS, Graham
  organization: Growth Factor Group. Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, United Kingdom
– sequence: 5
  givenname: Richard
  surname: POULSOM
  fullname: POULSOM, Richard
  organization: In-situ Hybridization Service, Cancer Research UK London Research Institute, London, United Kingdom
– sequence: 6
  givenname: Karena
  surname: LE MONNIER
  fullname: LE MONNIER, Karena
  organization: Department of Urology, Churchill Hospital, University of Oxford, Oxford, United Kingdom
– sequence: 7
  givenname: David W
  surname: CRANSTON
  fullname: CRANSTON, David W
  organization: Department of Urology, Churchill Hospital, University of Oxford, Oxford, United Kingdom
– sequence: 8
  givenname: Ji-Liang
  surname: LI
  fullname: LI, Ji-Liang
  organization: Growth Factor Group. Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, United Kingdom
– sequence: 9
  givenname: Adrian L
  surname: HARRIS
  fullname: HARRIS, Adrian L
  organization: Growth Factor Group. Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, United Kingdom
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18052132$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/16914569$$D View this record in MEDLINE/PubMed
BookMark eNpFkM1u1DAUhS1URH_gEUDegNSFW__HWUKYAlKrShVlaznOTWPwJIOdqPD2dZhBXfnK-s659neKjsZpBITeMnrBmDKXjFaGUCn4RdPcEaoJ5Ua9QCdMqYoIrtVRmf8zx-g055-UMsmofIWOma6ZVLo-QcP9jtzBwxLdHKYRTz3ejN00DxCDi_gzxNmRGH4BlnjzZ5cg5xVrppSgRCDjxzAP-Ee5h4hv3LykfVEY8afoug4SbtzoIb1GL3sXM7w5nGfo_mrzvflKrm-_fGs-XhMvKzoTpive1jUw1WpnwDvha6cNM21LeQXeMOUMpS0rr_dSQOW7vq-oVMIAk0KJM_Rh37tL0-8F8my3IXuI0Y0wLdlqUymutSmg2oM-TTkn6O0uha1Lfy2jdlVsV3121WeLYku1XRWX3LvDgqXdQvecOjgtwPsD4LJ3sU_l_yE_c4YqzgQv3PmeG8LD8BgSWP_PVJEMLvnBMl5KrTRCiyc98JQd
CitedBy_id crossref_primary_10_1016_j_juro_2008_02_037
crossref_primary_10_1042_BST20140233
crossref_primary_10_1007_s11912_023_01421_5
crossref_primary_10_2217_fon_10_62
crossref_primary_10_2353_ajpath_2010_090908
crossref_primary_10_1007_s13277_015_4312_3
crossref_primary_10_1007_s00418_007_0306_6
crossref_primary_10_1111_febs_13545
crossref_primary_10_1007_s12672_024_00992_4
crossref_primary_10_1158_0008_5472_CAN_14_3773
crossref_primary_10_4055_cios19117
crossref_primary_10_1016_j_cellsig_2014_07_034
crossref_primary_10_1016_j_canlet_2017_09_004
crossref_primary_10_1039_D0NR02962A
crossref_primary_10_1007_s12032_012_0390_x
crossref_primary_10_1038_nbt_1694
crossref_primary_10_1101_gad_1589207
crossref_primary_10_1038_nrc3035
crossref_primary_10_1158_1535_7163_MCT_10_0677
crossref_primary_10_1158_1535_7163_MCT_22_0243
crossref_primary_10_1161_ATVBAHA_111_232934
crossref_primary_10_18632_oncotarget_16969
crossref_primary_10_2147_OTT_S244860
crossref_primary_10_1074_jbc_M113_454850
crossref_primary_10_1093_carcin_bgp236
crossref_primary_10_1182_blood_2012_04_423004
crossref_primary_10_1182_blood_2008_07_170381
crossref_primary_10_1093_carcin_bgs386
crossref_primary_10_1097_MPA_0b013e3181ce7185
crossref_primary_10_1177_1358863X15570723
crossref_primary_10_1016_j_critrevonc_2021_103403
crossref_primary_10_1038_sj_bjc_6604484
crossref_primary_10_1053_j_gastro_2011_01_005
crossref_primary_10_1158_1535_7163_MCT_11_1027
crossref_primary_10_1016_j_mvr_2015_05_004
crossref_primary_10_1038_s41585_022_00608_y
crossref_primary_10_1007_s12032_016_0881_2
crossref_primary_10_1038_s12276_023_01114_w
crossref_primary_10_1038_nrc2130
crossref_primary_10_1186_1756_9966_32_26
crossref_primary_10_1016_j_cllc_2011_12_001
crossref_primary_10_1186_2045_824X_3_20
crossref_primary_10_1002_stem_1767
crossref_primary_10_1177_0300060513507388
crossref_primary_10_1186_s12885_017_3171_2
crossref_primary_10_3892_ol_2014_2554
crossref_primary_10_1159_000345116
crossref_primary_10_1007_s10620_007_0139_0
crossref_primary_10_3390_cancers13123089
crossref_primary_10_1038_onc_2008_227
crossref_primary_10_1182_blood_2010_05_284869
crossref_primary_10_1155_2012_261750
crossref_primary_10_1007_s10014_016_0256_6
crossref_primary_10_1093_neuonc_not071
crossref_primary_10_1111_j_1365_2559_2011_04138_x
crossref_primary_10_2217_fon_2020_0840
crossref_primary_10_3892_or_2012_2075
crossref_primary_10_1016_j_mvr_2007_06_006
crossref_primary_10_1089_thy_2010_0444
crossref_primary_10_1097_CCO_0000000000000406
crossref_primary_10_1016_j_humpath_2014_04_025
crossref_primary_10_4161_mabs_1_3_8515
crossref_primary_10_1097_SAP_0000000000000197
crossref_primary_10_1158_0008_5472_CAN_07_6499
crossref_primary_10_1186_1756_9966_32_46
crossref_primary_10_15406_jcpcr_2015_02_00059
crossref_primary_10_3390_cancers13040768
crossref_primary_10_1016_j_bbagen_2016_01_012
crossref_primary_10_1111_bph_15904
crossref_primary_10_1111_bju_13407
crossref_primary_10_3389_fonc_2023_1101055
crossref_primary_10_1245_s10434_011_1968_9
crossref_primary_10_1007_s10456_008_9098_0
crossref_primary_10_3389_fcell_2022_1027222
crossref_primary_10_1158_0008_5472_CAN_10_2719
crossref_primary_10_1016_j_molmed_2007_07_002
crossref_primary_10_1007_s10353_021_00707_x
crossref_primary_10_1073_pnas_2020057118
crossref_primary_10_1097_PAI_0b013e3181941794
crossref_primary_10_1158_1078_0432_CCR_07_1393
crossref_primary_10_1158_0008_5472_CAN_07_0969
crossref_primary_10_1158_0008_5472_CAN_11_1704
crossref_primary_10_1517_17460440903196737
crossref_primary_10_1038_bjc_2013_380
crossref_primary_10_4048_jbc_2019_22_e56
crossref_primary_10_1517_13543784_2012_661715
crossref_primary_10_1007_s10456_012_9318_5
crossref_primary_10_1007_s12032_014_0945_0
crossref_primary_10_1021_acs_jmedchem_5b01516
crossref_primary_10_1158_0008_5472_CAN_15_1227
crossref_primary_10_1021_acs_analchem_0c00057
crossref_primary_10_1016_j_canlet_2015_12_025
crossref_primary_10_2217_fon_11_20
crossref_primary_10_1016_j_apsb_2023_05_023
crossref_primary_10_1016_j_mvr_2012_03_004
crossref_primary_10_1038_sj_bjc_6605368
crossref_primary_10_1002_path_4340
crossref_primary_10_1038_bjc_2011_147
crossref_primary_10_1186_1471_2164_9_153
crossref_primary_10_3389_fonc_2021_771036
Cites_doi 10.1159/000019811
10.1161/hc0102.101437
10.1002/0471463752
10.1101/gad.1239204
10.1006/excr.2000.5034
10.1093/nar/29.9.e45
10.1006/mcne.1997.0612
10.1016/S0002-9440(10)63809-6
10.1002/jcp.10208
10.1101/gad.1239004
10.1056/NEJM198110083051506
10.1242/dev.126.14.3047
10.1073/pnas.0407290101
10.1097/00005392-199811000-00090
10.1073/pnas.250485597
10.1038/380435a0
10.1006/dbio.2000.9960
10.1038/380439a0
10.1056/NEJM197111182852108
10.1038/nm0603-685
10.1101/gad.14.11.1313
10.1182/blood-2005-03-1000
10.1016/S0959-437X(98)80115-9
10.1046/j.1432-0436.2001.690207.x
10.1126/science.277.5323.242
10.1016/S0960-7404(02)00013-0
10.1111/j.1749-6632.2003.tb03219.x
10.1016/S0002-9440(10)64920-6
10.1158/0008-5472.CAN-05-1208
10.1038/sj.onc.1205094
10.1126/science.7716513
10.1002/bies.20004
10.1073/pnas.091584598
10.1096/fj.04-1700fje
10.1101/gad.14.11.1343
10.1161/01.ATV.0000060892.81529.8F
10.1016/j.ccr.2005.06.013
10.1128/MCB.23.1.14-25.2003
10.1172/JCI5028
10.1038/nrc1186
ContentType Journal Article
Copyright 2006 INIST-CNRS
Copyright_xml – notice: 2006 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1158/1078-0432.CCR-06-0285
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1557-3265
EndPage 4844
ExternalDocumentID 10_1158_1078_0432_CCR_06_0285
16914569
18052132
12_16_4836
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID -
08R
29B
2WC
34G
39C
3O-
4H-
53G
55
5GY
5RE
5VS
AAPBV
ABFLS
ABOCM
ACIWK
ACPRK
ADACO
ADBBV
ADBIT
AENEX
AETEA
AFFNX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
C1A
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
FH7
FRP
GJ
GX1
H13
H~9
IH2
KQ8
L7B
LSO
MVM
O0-
OHT
OK1
P0W
P2P
RCR
RHF
RHI
RNS
SJN
UDS
VH1
W2D
WOQ
X7M
XFK
XJT
ZA5
ZCG
ZGI
---
.55
.GJ
18M
1CY
2FS
476
6J9
AAUGY
ACGFO
ACSVP
ADCOW
ADNWM
AFHIN
AFOSN
AI.
BR6
BTFSW
IQODW
J5H
QTD
TR2
W8F
WHG
YKV
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c470t-1672b99e15b6a8eca3c9a6818bb027ec815a800b1569c43e7cdff704538e14353
ISSN 1078-0432
IngestDate Sun Sep 29 07:26:10 EDT 2024
Thu Nov 21 21:02:43 EST 2024
Sat Sep 28 07:41:57 EDT 2024
Sun Oct 29 17:09:21 EDT 2023
Fri Jan 15 20:06:26 EST 2021
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 16
Keywords Endothelial cell
Urinary system disease
Blood vessel
Bladder disease
Circulatory system
Malignant tumor
Urinary tract disease
Gene expression
Bladder cancer
Endothelium
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c470t-1672b99e15b6a8eca3c9a6818bb027ec815a800b1569c43e7cdff704538e14353
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://aacrjournals.org/clincancerres/article-pdf/12/16/4836/1964116/4836.pdf
PMID 16914569
PQID 68752668
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_68752668
crossref_primary_10_1158_1078_0432_CCR_06_0285
pubmed_primary_16914569
pascalfrancis_primary_18052132
highwire_cancerresearch_12_16_4836
ProviderPackageCode RHF
RHI
PublicationCentury 2000
PublicationDate 2006-08-15
PublicationDateYYYYMMDD 2006-08-15
PublicationDate_xml – month: 08
  year: 2006
  text: 2006-08-15
  day: 15
PublicationDecade 2000
PublicationPlace Philadelphia, PA
PublicationPlace_xml – name: Philadelphia, PA
– name: United States
PublicationTitle Clinical cancer research
PublicationTitleAlternate Clin Cancer Res
PublicationYear 2006
Publisher American Association for Cancer Research
Publisher_xml – name: American Association for Cancer Research
References 2022061105055206000_B40
2022061105055206000_B1
2022061105055206000_B41
2022061105055206000_B8
2022061105055206000_B15
2022061105055206000_B37
2022061105055206000_B9
2022061105055206000_B16
2022061105055206000_B38
2022061105055206000_B6
2022061105055206000_B13
2022061105055206000_B35
2022061105055206000_B7
2022061105055206000_B14
2022061105055206000_B36
2022061105055206000_B4
2022061105055206000_B11
2022061105055206000_B33
2022061105055206000_B5
2022061105055206000_B12
2022061105055206000_B34
2022061105055206000_B2
2022061105055206000_B31
2022061105055206000_B3
2022061105055206000_B10
2022061105055206000_B32
2022061105055206000_B19
2022061105055206000_B17
2022061105055206000_B39
2022061105055206000_B18
2022061105055206000_B30
2022061105055206000_B26
2022061105055206000_B27
2022061105055206000_B24
2022061105055206000_B25
2022061105055206000_B22
2022061105055206000_B44
2022061105055206000_B23
2022061105055206000_B20
2022061105055206000_B42
2022061105055206000_B21
2022061105055206000_B43
2022061105055206000_B28
2022061105055206000_B29
References_xml – ident: 2022061105055206000_B28
  doi: 10.1159/000019811
– ident: 2022061105055206000_B40
  doi: 10.1161/hc0102.101437
– ident: 2022061105055206000_B22
  doi: 10.1002/0471463752
– ident: 2022061105055206000_B18
  doi: 10.1101/gad.1239204
– ident: 2022061105055206000_B31
– ident: 2022061105055206000_B34
  doi: 10.1006/excr.2000.5034
– ident: 2022061105055206000_B23
  doi: 10.1093/nar/29.9.e45
– ident: 2022061105055206000_B8
  doi: 10.1006/mcne.1997.0612
– ident: 2022061105055206000_B39
  doi: 10.1016/S0002-9440(10)63809-6
– ident: 2022061105055206000_B14
  doi: 10.1002/jcp.10208
– ident: 2022061105055206000_B17
  doi: 10.1101/gad.1239004
– ident: 2022061105055206000_B2
  doi: 10.1056/NEJM198110083051506
– ident: 2022061105055206000_B36
  doi: 10.1242/dev.126.14.3047
– ident: 2022061105055206000_B15
  doi: 10.1073/pnas.0407290101
– ident: 2022061105055206000_B25
  doi: 10.1097/00005392-199811000-00090
– ident: 2022061105055206000_B29
– ident: 2022061105055206000_B27
– ident: 2022061105055206000_B12
  doi: 10.1073/pnas.250485597
– ident: 2022061105055206000_B20
  doi: 10.1038/380435a0
– ident: 2022061105055206000_B10
  doi: 10.1006/dbio.2000.9960
– ident: 2022061105055206000_B19
  doi: 10.1038/380439a0
– ident: 2022061105055206000_B1
  doi: 10.1056/NEJM197111182852108
– ident: 2022061105055206000_B30
  doi: 10.1038/nm0603-685
– ident: 2022061105055206000_B35
  doi: 10.1101/gad.14.11.1313
– ident: 2022061105055206000_B42
  doi: 10.1182/blood-2005-03-1000
– ident: 2022061105055206000_B11
  doi: 10.1016/S0959-437X(98)80115-9
– ident: 2022061105055206000_B16
  doi: 10.1046/j.1432-0436.2001.690207.x
– ident: 2022061105055206000_B37
  doi: 10.1126/science.277.5323.242
– ident: 2022061105055206000_B3
  doi: 10.1016/S0960-7404(02)00013-0
– ident: 2022061105055206000_B24
– ident: 2022061105055206000_B33
  doi: 10.1111/j.1749-6632.2003.tb03219.x
– ident: 2022061105055206000_B32
  doi: 10.1016/S0002-9440(10)64920-6
– ident: 2022061105055206000_B21
  doi: 10.1158/0008-5472.CAN-05-1208
– ident: 2022061105055206000_B13
  doi: 10.1038/sj.onc.1205094
– ident: 2022061105055206000_B7
  doi: 10.1126/science.7716513
– ident: 2022061105055206000_B4
  doi: 10.1002/bies.20004
– ident: 2022061105055206000_B43
  doi: 10.1073/pnas.091584598
– ident: 2022061105055206000_B38
  doi: 10.1096/fj.04-1700fje
– ident: 2022061105055206000_B44
  doi: 10.1101/gad.14.11.1343
– ident: 2022061105055206000_B5
  doi: 10.1161/01.ATV.0000060892.81529.8F
– ident: 2022061105055206000_B6
  doi: 10.1016/j.ccr.2005.06.013
– ident: 2022061105055206000_B26
  doi: 10.1128/MCB.23.1.14-25.2003
– ident: 2022061105055206000_B41
  doi: 10.1172/JCI5028
– ident: 2022061105055206000_B9
  doi: 10.1038/nrc1186
SSID ssj0014104
Score 2.3006043
Snippet Purpose: Angiogenesis and vascular endothelial growth factor (VEGF) expression are associated with a poor outcome in bladder cancer. To understand more about...
Angiogenesis and vascular endothelial growth factor (VEGF) expression are associated with a poor outcome in bladder cancer. To understand more about the...
Purpose: Angiogenesis and vascular endothelial growth factor (VEGF) expression are associated with a poor outcome in bladder cancer. To understand more about...
PURPOSEAngiogenesis and vascular endothelial growth factor (VEGF) expression are associated with a poor outcome in bladder cancer. To understand more about the...
SourceID proquest
crossref
pubmed
pascalfrancis
highwire
SourceType Aggregation Database
Index Database
Publisher
StartPage 4836
SubjectTerms Actins - biosynthesis
Actins - genetics
Adult
Aged
Aged, 80 and over
angiogenesis
Antigens, CD34 - biosynthesis
Antigens, CD34 - genetics
Antineoplastic agents
Biological and medical sciences
bladder cancer
Carcinoma, Transitional Cell - blood supply
Carcinoma, Transitional Cell - genetics
Carcinoma, Transitional Cell - metabolism
Cohort Studies
Female
Humans
Immunohistochemistry
Intercellular Signaling Peptides and Proteins - biosynthesis
Intercellular Signaling Peptides and Proteins - genetics
Male
Medical sciences
Middle Aged
Neovascularization, Pathologic - genetics
Neovascularization, Pathologic - metabolism
Nephrology. Urinary tract diseases
Notch
Pharmacology. Drug treatments
Polymerase Chain Reaction
Prognosis
Tumors of the urinary system
Up-Regulation
Urinary Bladder Neoplasms - blood supply
Urinary Bladder Neoplasms - genetics
Urinary Bladder Neoplasms - metabolism
Urinary system involvement in other diseases. Miscellaneous
Urinary tract. Prostate gland
Vascular Endothelial Growth Factor A - biosynthesis
Vascular Endothelial Growth Factor A - genetics
Title Up-Regulation of Endothelial Delta-like 4 Expression Correlates with Vessel Maturation in Bladder Cancer
URI http://clincancerres.aacrjournals.org/content/12/16/4836.abstract
https://www.ncbi.nlm.nih.gov/pubmed/16914569
https://search.proquest.com/docview/68752668
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBAviG_Kx7AQb1VKHOfzEXWgARpCY5X2ZtmOo1VkadWlSOOv5y62k3ZsEvASVbHqpPn94t6df3dHyFuZZjrklQzKCrcZK5UEimseFFzxsvMQFAb0j76mh_P482lyOhpdbqmWNq2a6l_X5pX8D6pwDnDFLNl_QLafFE7AZ8AXjoAwHP8K4_kqWNte8s7sM02JGVU1hsFLU7cyqBc_zCTGQv5W8Iqq83WXwGJcYttPrB5eT86xwqf00kdV44q0Rk2YdvpdX87Ap1LaoYmrFtRHlb_BzFZmvajl5RBZPVgqZfdCnFJ_GDr2XbuuJg99b41r4WYTuq-GKPLAJmm6VTXEMr4x3112o216bS-icW5rovy5uid5F2hws01ns-NOtRXZrj9biK_OO8ixEhBYiMXwZ9dLEP3QLXIbayhi24WDT1_6DaiYdZ0n-2u55C-4g3fXXh-Lz7oZdy0cX3UaRbfyAuCpbMOUmz2azrI5uU_uOZeEvrf8ekBGpnlI7hw50cUjcrZDM7qs6BbN6EAzGtOBZnSgGUWaUUszOtCMLhrqaEYtlx6T-ccPJ7PDwDXoCHSchW3A0ixSRWFYolKZGy25LmQKJqBSYZQZnbNEgkOiGDwVHXOT6bKqMnAieG7QTudPyF6zbMwzQkOTR4xJcH4TFXOO7WB0KFlShiVnPMnHZOofqljZOiyi81-TXCAgAgERAIhAnSYAMiZv_KMX9kf490GwSLBUIMvGZH8HlGHqrtMHj8bktUdJwLqLm2myMcvNhUjB0QfjFm7sqQVv-K7jwfMbR16Qu8Nr8pLsteuNeQW2bav2Oxb-BoZAn_U
link.rule.ids 314,780,784,27924,27925
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Up-regulation+of+endothelial+delta-like+4+expression+correlates+with+vessel+maturation+in+bladder+cancer&rft.jtitle=Clinical+cancer+research&rft.au=Patel%2C+Nilay+S&rft.au=Dobbie%2C+Michael+S&rft.au=Rochester%2C+Mark&rft.au=Steers%2C+Graham&rft.date=2006-08-15&rft.issn=1078-0432&rft.volume=12&rft.issue=16&rft.spage=4836&rft_id=info:doi/10.1158%2F1078-0432.CCR-06-0285&rft_id=info%3Apmid%2F16914569&rft.externalDocID=16914569
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon